Therapeutic strategies for cardiogenic shock, 2006

被引：7

作者：

Ellis T.C. ^{[1
]}

Lev E. ^{[1
]}

Yazbek N.F. ^{[1
]}

Kleiman N.S. ^{[1
]}

机构：

[1] Department of Cardiology, Methodist Debakey Heart Center, Houston, TX 77030

来源：

Current Treatment Options in Cardiovascular Medicine | 2006年 / 8卷 / 1期

关键词：

Acute Myocardial Infarction; Systemic Inflammatory Response Syndrome; Cardiogenic Shock; Abciximab; Levosimendan;

D O I：

10.1007/s11936-006-0028-4

中图分类号：

学科分类号：

摘要：

Cardiogenic shock, a devastating consequence of acute myocardial infarction, is associated with extremely high mortality. Treatment strategies should focus on prompt reperfusion and hemodynamic support. The primary approach for therapy is emergent angiography and revascularization using percutaneous coronary intervention or coronary artery bypass surgery, with the assistance of intra-aortic balloon pump counterpulsation. Several adjunctive pharmacologic agents, particularly inotropic drugs and vasopressors, are also helpful for hemodynamic support. However, these agents have not been shown to provide a survival benefit, and their use is primarily based on clinical experience. Since our last publication, several important advances have been made in the understanding and treatment of cardiogenic shock. Recent evidence suggests that a systemic inflammatory response, including the upregulation of inducible nitric oxide synthase, complement activation, and an inflammatory cytokine cascade, play a role in the development of cardiogenic shock. Newer therapeutic strategies, including C5 inhibitors and nitric oxide synthase inhibitors, are being combined with traditional strategies, such as inotropic agents, vasopressors, and circulatory assist, to treat cardiogenic shock. Copyright © 2006 by Current Science Inc.

引用

页码：79 / 94

页数：15

共 77 条

[11]

Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2, Lancet, 2, pp. 349-360, (1988)

[12]

Kohsaka S., Menon V., Lowe A.M., Et al., Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock, Arch Intern Med, 165, pp. 1643-1650, (2005)

[13]

Hochman J.S., Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm, Circulation, 107, pp. 2998-3002, (2003)

[14]

Smart N., Mojet M., Latchman D.S., Et al., IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes, Cardiovasc Res, (2005)

[15]

Lehmann A., Boldt J., New pharmacological approaches for the perioperative treatment of ischemic cardiogenic shock, J Cardiothorac Vasc Anesth, 19, pp. 97-108, (2005)

[16]

Cohen M., Kelly R., Kong D., Et al., Pulmonary artery catheterization in acute coronary syndromes: Insights from the GUSTO IIb and GUSTO III trials, Am J Med, 118, pp. 482-488, (2005)

[17]

Fincke R., Hochman J.S., Lowe A., Et al., Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: A report from the SHOCK trial registry, J Am Coll Cardiol, 44, pp. 308-340, (2004)

[18]

Sanborn T., Sleeper L., Webb J., Correlates of one year survival in patients with cardiogenic shock complicating acute myocardial infarction: Angiographic findings from the SHOCK trial, J Am Coll Cardiol, 42, pp. 1373-1379, (2003)

[19]

Ryan T.J., Anderson J.L., Antman E.M., Et al., ACC/AHA guidelines for the management of patients with acute myocardial infarction, J Am Coll Cardiol, 28, pp. 1328-1428, (1996)

[20]

Tuttle R.R., Mills J., Dobutamine: Development of a new catecholamine to selectively increase cardiac contractility, Circ Res, 36, pp. 185-196, (1975)

← 1 2 3 4 5 6 7 8 →